Aytu Bioscience Inc (AYTU) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Aytu Bioscience Inc (NASDAQ:AYTU) in a report released on Monday morning. The firm issued a buy rating and a $9.00 price objective on the stock.

Shares of Aytu Bioscience (NASDAQ:AYTU) traded up 4.55% during mid-day trading on Monday, reaching $3.45. 150 shares of the company’s stock traded hands. Aytu Bioscience has a one year low of $3.01 and a one year high of $57.00. The firm’s 50-day moving average is $3.67 and its 200 day moving average is $4.84. The firm’s market cap is $17.49 million.

About Aytu Bioscience

Aytu Bioscience, Inc, formerly Rosewind Corporation, is a healthcare company. The Company is focused on developing treatments for urological and related conditions. The Company’s pipeline of products includes Zertane, and Zertane and a phosphodiesterase type 5 (PDE-5). The Company is conducting Phase III clinical development for its lead therapeutic candidate Zertane, an orally disintegrating tablet (ODT) formulated for the treatment of premature ejaculation (PE).

5 Day Chart for NASDAQ:AYTU

Receive News & Ratings for Aytu Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.